SōRSE on Bon Appétit: How To Find a CBD Product That Works

SōRSE on Bon Appétit: How To Find a CBD Product That Works

Imagine this scenario—you’re scanning the beverage aisle at your local grocery store. Between the cold brew coffee and sparkling waters, a new drink catches your eye with “CBD” emblazoned on the front. You remember hearing a lot about it and the purported health benefits. You’re curious, but you don’t really know where to start when it comes to understanding why or how you should be using CBD.

If you need some guidance, take a look at our feature in Bon Appétit on “How to Find a CBD Product That Works.”

SōRSE on Bon Appétit: How To Find a CBD Product That Works

 

SōRSE Partners with & Acquires Part of Cancer Research Group Pascal

Biotech Sorse and Pascal

VANCOUVER, British Columbia, & SEATTLE, Wash.– Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has entered into a Term Sheet with SōRSE Technology (“SōRSE”) to develop Pascal’s cannabinoid programs. Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials, led by Patrick Gray and his team of world-class medical researchers.

SōRSE Technology sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and over 12 months shelf stability. SōRSE Technology is science and data-driven, with 53 employees, 30 of whom specialize in R&D and Quality Assurance. SōRSE currently has multiple partnerships which provide a profitable revenue stream.

SōRSE technology will enable other cannabinoid researchers to build a network of doctors and scientists that can lead the world in offering cannabinoid health solutions. Pascal is the first company to identify a mechanism for cannabinoids to directly benefit cancer immunotherapy and is also developing a cannabinoid-derived drug targeting glioblastoma.

Pascal Biosciences is actively evaluating cannabinoid application research studies for potential participation. As a reputable cannabinoid industry leader, SōRSE Technology will partake in Pascal approved studies for the advancement of the industry and pharmaceutical applications.

“The potential of Pascal’s cannabinoid programs for clinical applications in combination with SōRSE’s proprietary emulsification methods offers a promising path for future medical applications of cannabinoid products,” said Dr. Patrick Gray, CEO of Pascal Biosciences. “This agreement comes on the heels of recent, successful collaborative efforts with SōRSE that allowed us to examine SōRSE formulations in several Pascal ongoing studies. The combination of SōRSE’s industry-leading technology with Pascal’s long-term biotech potential make this a meaningful transaction for our shareholders.”

“At SōRSE, we’re driven by our mission to help people better their lives through superior cannabinoid ingredients and delivery methods,” said SōRSE CEO Howard Lee. “We are excited to continue to support pharmaceutical studies of cannabinoids with the world-class researchers of Pascal Biosciences.”

About Pascal Biosciences Inc.

Pascal is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The Company’s portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. In addition, Pascal is developing a B-cell targeted antibody for acute lymphoblastic leukemia. Pascal will continue to work on this program, focusing on monoclonal antibodies for Acute Lymphoblastic Leukemia.

For more information, visit www.pascalbiosciences.com.

About SōRSE Technology

SōRSE Technology is a water-soluble emulsion technology designed for product developers to provide consumers with a better cannabis experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Their patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for seamless integration as an ingredient in food items, beverages, topicals, and medical applications.

SōRSE Technology currently powers more than 30 market-leading products in the cannabis, hemp and CBD industry. SōRSE‘s expertise allows for 360 degree solutions for product developers with minimal disruption to existing production procedures and methods. From sourcing ingredients to product formulation, the SōRSE team provides its partners unprecedented product safety and quality while optimizing compound bioavailability. Partnership opportunities include licensing, white labeling, product development, and cannabinoid research studies. SōRSE Technology is currently available in North America, South America, Europe, and Australia.

 

Contacts

Investor Contact:

invest@pascalbiosciences.com

Media Contacts:

Julie Rathbun for Pascal Biosciences

info@pascalbiosciences.com

Tel: 206-769-9219

Richard Laermer for SōRSE Technology
SorseTech@RLMpr.com

Tel: 212-741-5106 X 216

SōRSE Technology Announces Two New Members to Board of Directors

sorse drop

SōRSE Technology, the leading water-soluble CBD, hemp and terpene emulsion provider for infused CPG brands, announced today the appointment of two new members to its Board of Directors. Mary Wagner and Allen Hsieh’s tenures on SōRSE’s selective board will begin effective immediately.

Mary Wagner is a recognized executive leader and board director who has established a reputable career in the food industry for creating innovative products, managing risks and developing measures to ensure food quality and safety. Wagner is an industry veteran that has held key positions including Senior Vice President of Global Product Innovation, Food Safety, and Quality for Starbucks Coffee Company, General Manager of Mars Botanical, a division of Mars Candy, and Chief Technology and Quality Officer at E. and J. Gallo. She currently leads MK Wagner and Associates Inc., a solutions provider in innovation and food safety. In addition to serving on SōRSE Technology’s Board, Ms. Wagner also serves on the Board of Directors at Griffith Foods International, Jones Dairy, and Skagit Valley Malting. She also chairs the Food Safety Advisory Board for Ecolab. “I hope to contribute my knowledge in food and beverage, as well as my years of experience and connections with industry, government and academics to help make cannabinoids mainstream sooner rather than later,” said Wagner.

Allen Hsieh brings over 25 years of experience in business and finance to SōRSE’s board and has managed companies that generated $100 to $500 million in revenue annually. Mr. Hsieh’s broad financial background has spanned various industries, including all aspects of financial operations, reporting and internal controls, sale or divestitures of businesses and raising capital. Most recently, Mr. Hsieh served as the Chief Financial Officer for A Place for Mom, North America’s largest senior living and care referral service, where he successfully led the sale of the company from Warburg Pincus to Silver Lake Partners and General Atlantic. Mr. Hsieh has also served as the Chief Financial Officer for two publicly traded companies, Flow International and InfoSpace, Inc. He has successfully managed relationships between company boards and private equity groups with their respective stakeholders and currently serves as a Board Advisor to Ultrata based in Seattle. “Given how much progress has been made in the cannabis industry, this is an exciting space to work in, and I look forward to strategically positioning the company and its technology in the marketplace.”

“We are excited and honored to have attracted such a high caliber of talent to SōRSE Technology’s Board since both Mary and Allen have been associated with the best technology, food, and beverage brands in the world,” said SōRSE Technology CEO Howard Lee. “Our company has had a longstanding mission to make cannabinoid consumption as safe, accessible and enjoyable as possible and we look forward to tapping into Mary and Allen’s invaluable industry and business expertise to reach wider audiences.”